Opendata, web and dolomites

CAESAR SIGNED

Developing Therapeutic Antibodies for Pets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAESAR project word cloud

Explore the words cloud of the CAESAR project. It provides you a very rough idea of what is the project "CAESAR" about.

animal    launch    expensive    antibody    complete    pet    specializing    3k    canine    veterinary    put    royalties    cancer       reliance    display    2016    financial    animals    severe    emotional    owners    medical    ge    poorly    2million    40    phage    licensing    shifts    team    ownership    people    dogs    2018    overcome    caesar    demonstrated    solution    12    inflammation    companion    inflammatory    29bn    immunogenic    species    medicine    diseases    revenue    demographic    companions    biotech    human    expanding    chronic    pay    pets    treat    bowel    causes    15m    400    german    health    5k    cagr    adivo    hire    synthetic    suffering    causing    therapies    ibd    spend    global    market    library    generating    untenable    founded    therapeutic    therapeutics    distress    antibodies    sufficiently    synthesize    ineffective    scalable    gt    relieve    first    ease    generate    therapy    affordable    company    worth    native    managed   

Project "CAESAR" data sheet

The following table provides information about the project.

Coordinator
ADIVO GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADIVO GMBH DE (PLANEGG) coordinator 50˙000.00

Map

 Project objective

Chronic inflammatory diseases in pets such as Inflammatory Bowel Diseases (IBD) are poorly managed causing emotional and financial distress to pet owners. Current therapies are ineffective - they do not relieve pet suffering and lead to the animal being put down. Therapies are also expensive with costs up to €400/month. Antibody therapy for such conditions has long been used in human medicine but has not been sufficiently developed for veterinary medicine and causes an immunogenic response as the antibodies are not species specific. Antibodies need to be adapted which is expensive and causes severe side effects making them an untenable solution at present. Pet ownership in the EU has been on the increase (up by 2million pets since 2016) due to demographic shifts and a greater reliance on pets as companions. The global animal health market is worth > €29Bn growing at a CAGR of 6% with pet health making up 40% of the market. Pet owners spend €3k - €5k/ year on their pet’s health and are willing to pay to ease pet suffering. adivo is a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals. adivo was founded in 2018. The adivo-team aims to address medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in future. adivo has developed CAESAR, the first of a kind synthetic canine phage-display library to generate therapeutic antibodies for dogs. We have developed a complete library from which we can synthesize therapeutic antibodies native to treat IBD. Our solution will overcome the challenges of current therapies and provide an affordable, scalable solution for effective antibody therapy for pets which has been demonstrated in human medicine. We expect to generate out-licensing revenue ≥€15M when we launch the product before royalties and hire 12 people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAESAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAESAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More